HYPERION DEFI, INC.
HYPD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HYPD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HYPD
Hyperion Defi, Inc. (HYPD) is a biopharmaceutical company focused on developing and commercializing therapies for ophthalmic diseases, with a lead program in myopia progression and a history of financial challenges.
Key risk: Going concern risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$50.7M
Cash Runway
11.0 moLead Asset
clobetasol propionate ophthalmic suspension 0.05% (Approved)
Next Catalyst
Patent_Expiry · Jul 15, 2031Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 1 catalyst for HYPERION DEFI, INC..
Hyperion Defi, Inc. (HYPD) is a biopharmaceutical company focused on developing and commercializing therapies for ophthalmic diseases, with a lead program in myopia progression and a history of financial challenges.
- Cash and cash equivalents were $9.6M as of 2026-06-30 [sec].
- Total revenue was $0.4M for the period ended 2026-06-30 [sec].
- Net income was $31.0M for the period ended 2026-06-30 [sec].
- Shareholders' equity was $41.1M as of 2026-06-30 [sec].
- Total debt was $14.1M as of 2026-06-30 [sec].
What works
- The company has a lead product candidate, MicroPine, for myopia progression, with a large patient population and potential for significant market impact [sec · filed 2024-01-16].
- The company has a patent for MYDCOMBI expiring in 2031, indicating a period of exclusivity for that product [upcoming catalysts].
- The company has a history of raising capital through equity offerings and licensing arrangements, demonstrating some access to funding [sec_mda · as of 2025-04-15].
What to weigh
- The company has an accumulated deficit of approximately $200.9 million as of September 30, 2025, indicating significant historical losses [sec · filed 2025-12-10].
- The company has expressed substantial doubt about its ability to continue as a going concern, highlighting liquidity risk [sec_mda · as of 2025-04-15].
- The company has a history of negative cash flows from operations and may need to raise additional capital, which may not be available on reasonable terms [sec · filed 2025-12-10].
- The company's revenue is minimal ($0.4M as of 2026-06-30) and it has not yet generated significant product revenue [sec].
From the filings
Quoted directly from source documents.
The company has a significant accumulated deficit.
“As of September 30, 2025, we had cash and cash equivalents of $8.2 million and an accumulated deficit of approximately $200.9 million.”
SEC filings · December 10, 2025
The company has substantial doubt about its ability to continue as a going concern.
“based upon our current operating plan, there is substantial doubt about our ability to continue as a going concern for at least o”
SEC MD&A · April 15, 2025
Catalyst timeline
- 2031-07-15 · Patent_Expiry · MYDCOMBI — Patent/exclusivity expiry for MYDCOMBI, which may affect competitive positioning and revenue potential.
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern due to operating losses and cash needs [sec_mda · as of 2025-04-15].
- Capital raising risk — May need to raise additional capital, which may not be available on reasonable terms or at all [sec · filed 2025-12-10].
- Accumulated deficit — Accumulated deficit of approximately $200.9 million as of September 30, 2025 [sec · filed 2025-12-10].
- Minimal revenue — Total revenue was only $0.4M as of 2026-06-30, indicating lack of product sales [sec].
What to watch
- Ability to raise additional capital and maintain liquidity [sec · filed 2025-12-10].
- Progress of MicroPine clinical development and regulatory pathway [sec · filed 2024-01-16].
- Patent expiry of MYDCOMBI in 2031 and its impact on product exclusivity [upcoming catalysts].
- Any strategic partnerships or licensing deals to advance product candidates [sec · filed 2024-01-16].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run HYPERION DEFI, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HYPERION DEFI, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
11.0 months
D/E 0.11 · 20% dilution
Lead: Approved
5 candidates
1 upcoming, next in ~1780d
4 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
28
Total value held
$3.9M
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 237,986 | $821K |
| jane street group, llc | 128,280 | $443K |
| renaissance technologies llc | 115,641 | $399K |
| citadel advisors llc | 112,906 | $390K |
| vanguard capital management llc | 84,409 | $291K |
| blackrock, inc. | 81,108 | $280K |
| geode capital management, llc | 77,080 | $266K |
| oppenheimer & co inc | 64,268 | $222K |
| investment house llc | 51,875 | $179K |
| ubs group ag | 48,790 | $168K |
Showing top 10 of 28 institutional holders of HYPERION DEFI, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 9.5%
- Days to cover
- 3.0
- Shares short
- 1,040,944
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HYPD short interestGovernance
Frequently asked questions
What is the AI investment thesis for HYPERION DEFI, INC.?
Hyperion Defi, Inc. (HYPD) is a biopharmaceutical company focused on developing and commercializing therapies for ophthalmic diseases, with a lead program in myopia progression and a history of financial challenges.
What is HYPERION DEFI, INC.'s lead drug candidate?
HYPERION DEFI, INC.'s most advanced tracked candidate is clobetasol propionate ophthalmic suspension 0.05% (Approved) for post-operative inflammation and pain after ocular surgery.
What is HYPERION DEFI, INC.'s next catalyst?
HYPERION DEFI, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: MYDCOMBI" — expected July 15, 2031.
Who is the CEO of HYPERION DEFI, INC.?
Mr. Hyunsu Jung is the chief executive officer of HYPERION DEFI, INC. (HYPD).
Where is HYPERION DEFI, INC. headquartered?
HYPERION DEFI, INC. (HYPD) is headquartered in Dallas, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.